CEPs Will Detail ALL Plants in API Production Process, says EDQM

By Gareth Macdonald

- Last updated on GMT

Related tags: European union, Council of europe, Edqm

CEP Will List ALL Plants in API Production Chain, says EDQM
CEP Will List ALL Plants in API Production Chain, says EDQM
From next Monday CEPs issued by the EDQM will list details of all the manufacturing facilities involved in the production of APIs.

The idea is that detailing all third-party quality control, process testing, milling and sterilisation services providers as well as intermediates sources on certificates of suitability to the European Pharmacopoeia (CEP) will enhance traceability and quality.

The European Directorate for the Quality of Medicines and Healthcare (EDQM) told “This information has always been part of the application. The change is that now it will be reported on CEPs, which was not the case before when only the holder and the final manufacturer were mentioned.

The change brought to CEPs does not affect the content of the applications, but the information on the CEPs themselves.”

The EDQM also told us that, while it has not yet happened “theoretically, an applicant that fails to provide this information risks to have its application rejected and no CEP issued.”

Holders of CEPs issued before the July 15 are required to communicate details of the additional manufacturing sites to customers.

Whether CEP holders that fail to do this risk losing certification is unclear as the EDQM told us that: “This is something that is outside of our control​.”

Rule change

The revision is the first major change to the CEPs since 2011 when the EDQM asked active pharmaceutical ingredient (API) manufacturers to provide the precise locations of their plants using Google Earth​.

Details of the manufacturing facilities can be either a DUNS number – which is a system devised by Dun & Bradstreet that assigns a unique digit numeric identifier to each plant – or a set of global positioning satellite (GPS) co-ordinates.

The new requirement will follow just weeks after new laws requiring all APIs shipped to the European Union (EU) be accompanied by written confirmation from local regulators they were made to the same standards as those produced in Europe.

Related news

Show more

Related products

show more

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us


View more